The 23 linked references in paper E. Shatokhina A., L. Kruglova S., Е. Шатохина А., Л. Круглова С. (2019) “Акнеподобная сыпь - кожная токсическая реакция на применение ингибиторов EGFR // Acneiform rash — skin toxic reaction to the use of EGFR inhibitors” / spz:neicon:ogsh:y:2018:i:4:p:48-55

  1. 05;23(22):5235–46. DOI: 10.1200/JCO.2005.00.6916. PMID: 16051966. 2. Joshi S. S., Ortiz S., Witherspoon J. N. et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116(16):3916–23. DOI: 10.1002/cncr.25090. PMID: 20564072.
  2. Boone S. L., Rademaker A., Liu D. et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72(3–4):152–9. DOI: 10.1159/000112795. PMID: 18160805.
  3. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(9):1425–33. DOI: 10.1093/annonc/mdi279. PMID: 16012181.
  4. Segaert S., Chiritescu G., Lemmens L. et al. Skin toxicities of targeted therapies. Eur J Cancer 2009;45(Suppl 1):295–308. DOI: 10.1016/S0959-8049(09)70044-9. PMID: 19775626.
  5. Perez-Soler R., Delord J. P., Halpern A. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10(5):345–56. DOI: 10.1634/ theoncologist.10-5-345. PMID: 15851793.
  6. Robert C., Soria J. C., Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6(7):491–500. DOI: 10.1016/S14702045(05)70243-6. PMID: 15992698.
  7. Jacot W., Bessis D., Jorda E. et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151(1):238–41. DOI: 10.1111/j.1365-2133.2004.06026.x. PMID: 15270903.
  8. Galimont-Collen A. F., Vos L. E., Lavrijsen A. P. et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor(EGFR) inhibitors. Eur J Cancer 2007;43(5):845–51. DOI: 10.1016/j.ejca.2006.11.016. PMID: 17289377.
  9. Agero A. L., Dusza S. W., BenvenutoAndrade C. et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55(4):657–70. DOI: 10.1016/j. jaad. 2005.10.010. PMID: 17010747.
  10. Roé E., Garcia Muret M. P., Marcuello E. et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006;55(3):429–37.DOI: 10.1016/j.jaad. 2006.04.062. PMID: 16908348.
  11. Wacker B., Nagrani T., Weinberg J. et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13(13):3913–21. DOI: 10.1158/1078-0432.CCR-06-2610. PMID: 17606725.
  12. Fernández-Torres R., Martinez Gomez W., Cuevas Santos J. et al. Rosaceiform eruption induced by cetuximab. Eur J Dermatol 2010;20(3):392–3. DOI: 10.1684/ejd. 2010.0900. PMID: 20172848.
  13. Wolf M., Swaisland H., Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004;10(14):4607–13. DOI: 10.1158/1078-0432.CCR-04-0058. PMID: 15269131.
  14. Peeters M., Siena S., Van Cutsem E. et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115(7):1544–54. DOI: 10.1002/cncr.24088. PMID: 19189371.
  15. Cutsem E., Tejpar S., Vanbeckevoort D. et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012;30(23):2861–8. DOI: 10.1200/JCO.2011.40.9243. PMID: 22753904.
  16. Shepherd F. A., Rodrigues Pereira J., Ciuleanu T. et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123–32. DOI: 10.1056/NEJMoa050753. PMID: 16014882.
  17. Perez-Soler R., Chachoua A., Hammond L. A. et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238–47. DOI: 10.1200/ JCO.2004.11.057. PMID: 15310767.
  18. Ouwerkerk J, Boers-Doets C Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010;14(4):337–49. DOI: 10.1016/j. ejon.2010.03.004. PMID: 20580896.
  19. Bernier J., Bonner J., Vermorken J. B. et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142–9. DOI: 10.1093/annonc/ mdm400. PMID: 17785763.
  20. Jatoi A., Green E. M., Rowland K. M. Jr et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009;77(2):120–3. DOI: 10.1159/ 000229751. PMID: 19622902.
  21. Cunningham D., Humblet Y., Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337–45. DOI: 10.1056/NEJMoa033025. PMID: 15269313.
  22. Togashi Y., Masago K., Fujita S. et al. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with nonsmall cell lung cancer. Lung Cancer 2011;74(1):98–102. DOI: 10.1016/j. lungcan.2011.01.022. PMID: 21377230.
  23. Grenader T., Gipps M., Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9(1):59–60. DOI: 10.3816/CLC.2008.n.010. PMID: 18282360.